Platinum resistance is a major contributor to ovarian cancer mortality and presents a considerable clinical challenge, necessitating the development of better treatments for platinum-resistant patients. In this editorial, A/Prof. David Tan and Dr Wijaya discuss the findings made in the recently published AMBITION study, an umbrella-design, biomarker-driven trial for patients with platinum-resistant recurrent ovarian cancer. They highlight the importance of the trial for the development of precision oncology for the treatment of recurrent ovarian cancer.

Read more: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250860/